De­spite Phase 3 win, Roche says rare au­toim­mune drug did­n't meet ex­pec­ta­tions

Roche’s Chugai Phar­ma­ceu­ti­cal said its im­mune dis­ease drug En­spryng didn’t pro­duce the re­sults it was hop­ing for in a Phase 3 study in gen­er­al­ized myas­the­nia gravis, an au­toim­mune dis­or­der that leads to weak­ness in vol­un­tary mus­cles.

En­spryng hit the pri­ma­ry end­point of the study, which mea­sured change on a scale of the dis­or­der’s im­pact on dai­ly func­tions at 24 weeks. But “the re­sults did not reach our ex­pec­ta­tions on the de­gree of clin­i­cal ben­e­fit,” Chugai said Thurs­day in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER